Founded in 1950, Zenyaku Kogyo is a privately-held Japanese company that specializes in the research and development of drugs for cancer and autoimmune diseases. With headquarters in Tokyo, the company is known for its dermatological and anti-cancer drugs, including RituxanTM, used in the treatment of B-cell Non-Hodgkin’s Lymphoma. In addition to its pharmaceutical business, Zenyaku Kogyo also operates in the consumer health care sector. The company's ongoing research interests are centered around cancer, autoimmune diseases, and antibody therapeutics.